Core Points - Huabang Health announced that its wholly-owned subsidiary, Chongqing Huabang Pharmaceutical Co., Ltd., has received the drug registration certificates for two specifications of Mometasone Furoate Cream from the National Medical Products Administration [2] Group 1 - The approval of Mometasone Furoate Cream is a significant milestone for the company, enhancing its product portfolio in the pharmaceutical sector [2] - The registration certificates indicate compliance with regulatory standards, which may facilitate market entry and sales growth for the company [2]

Core Viewpoint - Huabang Health has received approval for the registration of Mometasone Furoate Cream from the National Medical Products Administration, which may enhance its product portfolio and revenue potential [1] Company Summary - Huabang Health's subsidiary, Chongqing Huabang Pharmaceutical Co., Ltd., has obtained two specifications of the drug registration certificate for Mometasone Furoate Cream [1] - As of the latest report, Huabang Health has a market capitalization of 9.3 billion yuan [1] Industry Summary - For the first half of 2025, Huabang Health's revenue composition is as follows: pesticides account for 56.82%, pharmaceuticals for 27.33%, tourism for 8.29%, others for 4.34%, and medical services for 3.21% [1]

Group 1 - The company Huabang Health (002004.SZ) announced that its wholly-owned subsidiary, Chongqing Huabang Pharmaceutical Co., Ltd., has recently received the drug registration certificate from the National Medical Products Administration for two specifications of Mometasone Furoate Cream [1] - Mometasone Furoate Cream is primarily used for the treatment of eczema, neurodermatitis, atopic dermatitis, and pruritus [1]

格隆汇9月16日丨华邦健康(002004.SZ)公布，公司全资子公司重庆华邦制药有限公司（称"华邦制药"） 于近日收到国家药品监督管理局核准签发的关于糠酸莫米松乳膏的两个规格的《药品注册证书》，糠酸 莫米松乳膏主要用于湿疹、神经性皮炎、异位性皮炎及皮肤瘙痒症。 ...

Core Viewpoint - Huabang Health (002004.SZ) announced that its wholly-owned subsidiary, Chongqing Huabang Pharmaceutical Co., Ltd., has received the drug registration certificates for two specifications of Mometasone Furoate Cream from the National Medical Products Administration. The cream is primarily used for eczema, neurodermatitis, atopic dermatitis, and pruritus [1] Group 1 - The drug registration certificates were issued for two specifications of Mometasone Furoate Cream [1] - Mometasone Furoate Cream is indicated for the treatment of eczema, neurodermatitis, atopic dermatitis, and skin itching [1]

Core Viewpoint - Huabang Health's subsidiary Huabang Pharmaceutical has received approval from the National Medical Products Administration for the drug registration certificate of Mometasone Furoate Cream in two specifications, indicating a significant regulatory milestone for the company [1] Company Summary - Huabang Pharmaceutical's Mometasone Furoate Cream is primarily used for treating eczema, neurodermatitis, atopic dermatitis, and pruritus [1] - The drug was registered as a Class 3 chemical generic drug, which is considered equivalent to passing the consistency evaluation [1]

Group 1 - The genetically modified (GM) concept sector declined by 0.79% as of the market close on September 16, ranking among the top declines in concept sectors, with companies like Batian Co., KQ Biotech, and Dunhuang Seed Industry experiencing significant drops [1] - The GM concept sector saw a net outflow of 153 million yuan in main funds today, with 13 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 10 million yuan. The stock with the highest net outflow was Shennong Seed Industry, with a net outflow of 30.19 million yuan [2] - Other companies with notable net outflows included Dunhuang Seed Industry, Nongfa Seed Industry, and Jincheng Pharmaceutical, with net outflows of 23.78 million yuan, 22.76 million yuan, and 21.20 million yuan respectively [2] Group 2 - The top net inflow stocks in the GM concept sector included KQ Biotech and Guotou Fengle, with net inflows of 4.89 million yuan and 0.99 million yuan respectively [3] - The GM concept sector's outflow leaderboard featured Shennong Seed Industry, Dunhuang Seed Industry, Nongfa Seed Industry, and Jincheng Pharmaceutical, all showing negative performance in terms of stock price changes [2][3]

证券代码：002004 证券简称：华邦健康 公告编号：2025046 华邦生命健康股份有限公司 关于全资子公司获得《药品注册证书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）全资子公司重庆华邦制药 有限公司（以下简称"华邦制药"）于近日收到国家药品监督管理局核准签发的 关于糠酸莫米松乳膏的两个规格的《药品注册证书》，现将有关情况公告如下： 一、药品基本情况 1、药品名称：糠酸莫米松乳膏 2、剂型：乳膏剂 3、规格：0.1%（按 C₂₇H₃₀C₁₂O₆计）（30g：30mg）；0.1%（按₂₇H₃₀Cl₂O₆计） （15g：15mg） 4、注册分类：化学药品 3 类 5、受理号：CYHS2400262；CYHS2400263 6、药品批准文号：国药准字 H20255359；国药准字 H20255360 7、证书编号：2025S02757；2025S02758 糠酸莫米松乳膏主要用于湿疹、神经性皮炎、异位性皮炎及皮肤瘙痒症。 三、对公司的影响 1 公司子公司华邦制药收到国家药品监督管理局颁发的关于糠酸莫米松乳 ...

Core Viewpoint - Huabang Health (002004) announced on September 9 that Pruijin has completed the listing guidance filing for the Beijing Stock Exchange, with further updates to be provided in subsequent announcements [1] Company Summary - Pruijin is a company focused on cell therapy CDMO (Contract Development and Manufacturing Organization) services, having established specialized platforms for nucleic acids, serum-free virus production, closed cell process development, and quality control testing [1] - The company offers a comprehensive range of services from drug discovery to IIT (Investigator Initiated Trials) non-registered clinical trials, and from sequence development to IND (Investigational New Drug) application [1]

Group 1 - The company Huabang Health announced a cash dividend distribution plan for the first half of 2025, proposing a payout of 2 yuan (including tax) for every 10 shares held by shareholders [2] - The record date for the stock rights is set for September 15, 2025, and the ex-dividend date is September 16, 2025 [2]